REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) Debt-to-equity % [USD] 2019 - 2024

Historical data

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Reviva Pharmaceuticals Holdings, Inc. quarterly Debt-to-equity history and growth rate from 2019 to 2024.
  • Reviva Pharmaceuticals Holdings, Inc. Debt-to-equity for the quarter ending March 31, 2024 was -631 %, a 937% decline year-over-year.
Debt-to-equity, Quarterly (% [USD])
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q1 2024 -631 -706 -937% Mar 31, 2024
Q4 2023 -838 -878 -2182% Dec 31, 2023
Q3 2023 -1.16 K -1.18 K -5596% Sep 30, 2023
Q2 2023 163 +150 +1149% Jun 30, 2023
Q1 2023 75.4 +66.6 +758% Mar 31, 2023
Q4 2022 40.3 +31.8 +374% Dec 31, 2022
Q3 2022 21.2 +9.32 +78.8% Sep 30, 2022
Q2 2022 13 -19.9 -60.5% Jun 30, 2022
Q1 2022 8.78 +202 Mar 31, 2022
Q4 2021 8.5 +85.6 Dec 31, 2021
Q3 2021 11.8 +70 Sep 30, 2021
Q2 2021 33 +124 Jun 30, 2021
Q1 2021 -193 +140 +42.1% Mar 31, 2021
Q4 2020 -77.1 -242 -147% Dec 31, 2020
Q3 2020 -58.2 -157 -159% Aug 31, 2020
Q2 2020 -90.9 -190 -192% May 31, 2020
Q1 2020 -333 Feb 29, 2020
Q4 2019 165 Dec 31, 2019
Q3 2019 99.2 Aug 31, 2019
Q2 2019 98.8 May 31, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.